心房颤动导管消融术后长期停用抗凝治疗:ALONE-AF随机临床试验
该随机临床试验纳入840例导管消融后至少1年无房性心律失常复发且有至少1项非性别相关卒中危险因素的成人患者,1:1分为停用口服抗凝药组(417例)与继续直接口服抗凝药组(423例)。2年时主要复合终点(卒中、系统性栓塞和大出血)停用组1例(0.3%)vs 继续组8例(2.2%),绝对差-1.9个百分点(95%CI -3.5至-0.3;P=0.02)。结论认为停用口服抗凝药较继续直接口服抗凝药降低该复合结局风险。
要点
- 消融后至少1年无房性心律失常复发且CHA2DS2-VASc评分提示有卒中危险因素者,停用抗凝组2年主要复合终点发生率0.3% vs 继续组2.2%。
- 2年缺血性卒中累积发生率停用组0.3% vs 继续组0.8%,绝对差-0.5个百分点(95%CI -1.6至0.6)。
- 2年大出血停用组0例 vs 继续组5例(1.4%),绝对差-1.4个百分点(95%CI -2.6至-0.2)。
核心结论
- 在房颤导管消融后无房性心律失常复发记录的患者中,停用口服抗凝药较继续直接口服抗凝药降低卒中、系统性栓塞和大出血复合结局风险。
研究设计与样本
- 随机临床试验,2020年7月28日至2023年3月9日在韩国18家医院入组并随机840例19-80岁成人患者。
- 纳入标准为至少1项非性别相关卒中危险因素(采用CHA2DS2-VASc评分,范围0-9)且房颤导管消融后至少1年无房性心律失常复发记录。
- 患者按1:1随机分为停用口服抗凝药组(n=417)与继续口服抗凝药(直接口服抗凝药)组(n=423),最终随访日期为2025年6月4日。
主要发现
- 840例随机患者平均年龄64岁(SD 8),女性占24.9%,平均CHA2DS2-VASc评分2.1(SD 1.0),67.6%为阵发性房颤。
- 2年主要终点(卒中、系统性栓塞和大出血复合)停用组1例(0.3%)vs 继续组8例(2.2%),绝对差-1.9个百分点(95%CI -3.5至-0.3;P=0.02)。
- 2年缺血性卒中累积发生率停用组0.3% vs 继续组0.8%,绝对差-0.5个百分点(95%CI -1.6至0.6)。
- 大出血停用组0例 vs 继续组5例(1.4%),绝对差-1.4个百分点(95%CI -2.6至-0.2)。
关键数值与推荐
- 主要终点为2年时卒中、系统性栓塞和大出血复合结局的首次发生。
- 次要结局包括主要终点的各单项组分(如缺血性卒中和大出血)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Data from randomized clinical trials on a long-term anticoagulation strategy for patients after catheter-based ablation for atrial fibrillation (AF) are lacking. OBJECTIVE: To evaluate whether discontinuing oral anticoagulant therapy provides superior clinical outcomes compared with continuing oral anticoagulant therapy in patients without documented atrial arrhythmia recurrence after catheter ablation for AF. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial including 840 adult patients (aged 19-80 years) who were enrolled and randomized from July 28, 2020, to March 9, 2023, at 18 hospitals in South Korea. Enrolled patients had at least 1 non-sex-related stroke risk factor (determined using the CHA2DS2-VASc score [range, 0-9]) and no documented recurrence of atrial arrhythmia for at least 1 year after catheter ablation for AF. The CHA2DS2-VASc score is used as an assessment of stroke risk among patients with AF (calculated using point values for congestive heart failure, hypertension, ≥75 years of age, diabetes, stroke or transient ischemic attack, vascular disease, between 65 and 74 years of age, and sex category). The date of final follow-up was June 4, 2025. INTERVENTIONS: The patients were randomly assigned in a 1:1 ratio to discontinue oral anticoagulant therapy (n = 417) or continue oral anticoagulant therapy (with direct oral anticoagulants; n = 423). MAIN OUTCOMES AND MEASURES: The primary outcome was the first occurrence of a composite of stroke, systemic embolism, and major bleeding at 2 years. Individual components of the primary outcome (such as ischemic stroke and major bleeding) were assessed as secondary outcomes. RESULTS: Of the 840 adults randomized, the mean age was 64 (SD, 8) years, 24.9% were women, the mean CHA2DS2-VASc score was 2.1 (SD, 1.0), and 67.6% had paroxysmal AF. At 2 years, the primary outcome occurred in 1 patient (0.3%) in the discontinue oral anticoagulant therapy group vs 8 patients (2.2%) in the continue oral anticoagulant therapy group (absolute difference, -1.9 percentage points [95% CI, -3.5 to -0.3]; P = .02). The 2-year cumulative incidence of ischemic stroke was 0.3% in the discontinue oral anticoagulant therapy group vs 0.8% in the continue oral anticoagulant therapy group (absolute difference, -0.5 percentage points [95% CI, -1.6 to 0.6]). Major bleeding occurred in 0 patients in the discontinue oral anticoagulant therapy group vs 5 patients (1.4%) in the continue oral anticoagulant therapy group (absolute difference, -1.4 percentage points [95% CI, -2.6 to -0.2]). CONCLUSIONS AND RELEVANCE: Among patients without documented atrial arrhythmia recurrence after catheter ablation for AF, discontinuing oral anticoagulant therapy resulted in a lower risk for the composite outcome of stroke, systemic embolism, and major bleeding vs continuing direct oral anticoagulant therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04432220.
引用
- Kim D, Shim J, Choi EK, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025. PMID: 40886309. doi:10.1001/jama.2025.14679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。